Table 1 |
||||
|
Summary of results for all tumour xenografts |
||||
|
Tumour model |
CNR calculated by FRI (AU)a |
FMT (nmol/l) |
VVF (%)b |
BVPD (BVPs/mm2) |
|
|
||||
|
MDA-MB435: melanoma |
389 ± 72 (n = 10) |
229 ± 90 (n = 4) |
3.58 ± 0.9 (n = 4) |
399 ± 36 (n = 6) |
|
HT1080: fibrosarcoma |
232 ± 99 (n = 11) |
92 ± 65 (n = 5) |
1.9 ± 0.7 (n = 4) |
128 ± 38 (n = 6) |
|
MCF7: adenocarcinoma |
185 ± 57 (n = 9) |
65 ± 50 (n = 6) |
0.75 ± 0.5 (n = 4) |
59 ± 10 (n = 6) |
|
DU4475: adenocarcinoma |
167 ± 79 (n = 13) |
49 ± 22 (n = 4) |
0.8 ± 0.5 (n = 4) |
78 ± 16 (n = 6) |
|
|
||||
|
Data are expressed as mean ± standard deviation. Note that the data generated by fluorescence imaging technologies (FRI, FMT) correlate well with in in vivo (VVF) and ex vivo (BVDP) surrogate markers of tumour angiogenesis. aCalculated 24 hours after intravenous injection of SIDAG. bMeasured using magnetic resonance imaging. AU, arbitrary units; BVP, blood vessel profile; BVPD: blood vessel profiles density; FMT, fluorescence-mediated tomography; FRI, fluorescence reflectance imaging; VVF, vascular volume fraction. |
||||
|
Wall et al. Breast Cancer Research 2008 10:R23 doi:10.1186/bcr1875 |
||||
